Tests liver-directed tirapazamine embolization with pembrolizumab for liver-spread cancers
Tests a combined liver treatment with pembrolizumab in adults with colorectal or lung cancer.
Plain-language title generated from the registry record
Registry title: TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Key facts
- Where
- Hsinchu and Taichung, TaiwanSee the 2 sites
- Phase
- Phase 2
Where in Taiwan
- China Medical University Hsinchu HospitalHsinchu, TaiwanTaking people
- Chung Shan Medical University HospitalTaichung, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Teclison Ltd.
- Trial code
- NCT04701476
- Record updated
- 16 April 2026
- Original description
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.Read full original descriptionShow less
An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
Inclusion: Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations; mCRC progressed on at least two lines of standard chemotherapy; or; NSCLC progressed on chemotherapy and an immune checkpoint inhibitor; Measurable disease; ECOG 0-1; At least 4 weeks from prior chemotherapy and free from chemo-related toxicity; Adequate organ function.
Exclusion: Prior organ transplantation; Prior autoimmune disorder; Major GI bleeding in the last 2 months; Liver metastasis more than 50%; Oxygen saturation less than 92% in room air; CNS metastasis.